<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="26643">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01772615</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2009-10</org_study_id>
    <nct_id>NCT01772615</nct_id>
  </id_info>
  <brief_title>Treatment of Ulcerative Colitis With Ciprofloxacin and E. Coli Nissle</brief_title>
  <official_title>Active Ulcerative Colitis; Placebo Controlled Treatment Trial With Ciprofloxacin and E. Coli Nissle</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hvidovre University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hvidovre University Hospital</source>
  <oversight_info>
    <authority>Denmark: The Regional Committee on Biomedical Research Ethics</authority>
    <authority>Denmark: Danish Dataprotection Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Purpose: The purpose of the study is to investigate if treatment with ciprofloxacin for one
      week followed by therapy with E. Coli Nissle (EcN) for seven weeks can influence disease
      activity among ulcerative colitis patients with disease flare-ups compared to placebo
      controls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ulcerative colitis (UC) is a chronic inflammatory bowel disease where existing treatments
      have proven to result in numerous side effects. An important causal factor for the
      development of the disease is an autoimmune cellular response against bacteria in the colon.

      As a possible treatment, manipulation of the bacterial flora has been studied using the
      probiotic bacterium Escherichia coli Nissle 1917 (EcN). Studies on UC patients have shown
      that treatment with EcN is equally good at maintaining remission as the standard treatment
      with mesalazine. Furthermore, treatment with antibiotics such as ciprofloxacin have been
      studied for treatment of UC and some, but shortlived, effect has been described.

      Patients are randomized to one of four treatment-arms: ciprofloxacin-EcN,
      ciprofloxacin-placebo, placebo-EcN or placebo-placebo.

      Disease activity are quantitated with Colitis Activity Index (CAI) and quality of life by
      the Inflammatory Bowel Disease Questionnaire (IBDQ). Also, dietary interviews to examine the
      patients' dietary intake are completed and the patients' fecal-calprotectin-concentrations
      will be measured.

      Hundred subjects with ulcerative colitis will be recruited for the study. Standard medical
      care and therapies will be continued throughout the study
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">August 2013</completion_date>
  <primary_completion_date type="Actual">August 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Bio-equivalence Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Compare number of participants in remission</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare number of participants in remission (CAI &lt;/=4) in the four groups. Compare time to the patients achieve remission (CAI &lt;/=4) in the four groups</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compare numbers of patients who completed the study in the 4 groups</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Compare numbers of patients who completed the study in the 4 groups Compare IBDQ-score in the 4 groups Compare dietary intake in the 4 groups Compare the possible side effects of treatment in the different groups</description>
  </secondary_outcome>
  <other_outcome>
    <measure>E. coli strains</measure>
    <time_frame>12 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Compare changes in E. coli strains in the 4 groups</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Ulcerative Colitis</condition>
  <arm_group>
    <arm_group_label>ciprofloxacin-EcN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ciprofloxacin-placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo-EcN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo-placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciprofloxacin</intervention_name>
    <description>Antibiotic</description>
    <arm_group_label>ciprofloxacin-EcN</arm_group_label>
    <arm_group_label>ciprofloxacin-placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>E. coli Nissle</intervention_name>
    <description>Probiotic</description>
    <arm_group_label>ciprofloxacin-EcN</arm_group_label>
    <arm_group_label>placebo-EcN</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age, &gt;/=18 years and diagnosed with ulcerative colitis

          -  CAI score of &gt;/=6 (active UC)

        Exclusion Criteria:

          -  Pregnant or breastfeeding females

          -  Known sensitivity to ciprofloxacin

          -  Subjects who participate in another clinical trial

          -  Positive stool sample with any enteric pathogens, parasites or     Clostridium
             difficile

          -  Treatment with systemic corticosteroids or biologic therapy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas M Petersen, MD, ph.d.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Andreas M Petersen, MD, ph.d.</last_name>
    <role>Study Chair</role>
    <affiliation>Hvidovre University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hvidovre Hospital, Copenhagen University</name>
      <address>
        <city>Hvidovre</city>
        <state>Copenhagen</state>
        <zip>2650</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <link>
    <url>http://www.ssi.dk/Service/Sygdomsleksikon/C/~/media/Indhold/DK%20-%20dansk/Sygdomsleksikon/colitis%20ulcerosaE%20coli%20Nissle%20projekt.ashx</url>
  </link>
  <reference>
    <citation>Vejborg RM, Hancock V, Petersen AM, Krogfelt KA, Klemm P. Comparative genomics of Escherichia coli isolated from patients with inflammatory bowel disease. BMC Genomics. 2011 Jun 15;12:316. doi: 10.1186/1471-2164-12-316.</citation>
    <PMID>21676223</PMID>
  </reference>
  <reference>
    <citation>Petersen AM, Nielsen EM, Litrup E, Brynskov J, Mirsepasi H, Krogfelt KA. A phylogenetic group of Escherichia coli associated with active left-sided inflammatory bowel disease. BMC Microbiol. 2009 Aug 20;9:171. doi: 10.1186/1471-2180-9-171.</citation>
    <PMID>19695087</PMID>
  </reference>
  <verification_date>August 2013</verification_date>
  <lastchanged_date>August 9, 2013</lastchanged_date>
  <firstreceived_date>January 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hvidovre University Hospital</investigator_affiliation>
    <investigator_full_name>Andreas Munk Petersen</investigator_full_name>
    <investigator_title>MD, ph.d.</investigator_title>
  </responsible_party>
  <keyword>EcN, Nissle, Mutaflor, Ulcerative Colitis, antibiotics, Inflammatory Bowel Diseases</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Colitis</mesh_term>
    <mesh_term>Colitis, Ulcerative</mesh_term>
    <mesh_term>Ulcer</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Ciprofloxacin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
